| Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma N Fujiwara, H Nakagawa, Y Kudo, R Tateishi, M Taguri, T Watadani, ... Journal of hepatology 63 (1), 131-140, 2015 | 716 | 2015 |
| Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine N Fujiwara, SL Friedman, N Goossens, Y Hoshida Journal of hepatology 68 (3), 526-549, 2018 | 663 | 2018 |
| A simple diet-and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer T Tsuchida, YA Lee, N Fujiwara, M Ybanez, B Allen, S Martins, MI Fiel, ... Journal of hepatology 69 (2), 385-395, 2018 | 525 | 2018 |
| Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma JSV Lally, S Ghoshal, DK DePeralta, O Moaven, L Wei, R Masia, ... Cell metabolism 29 (1), 174-182. e5, 2019 | 324 | 2019 |
| HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response N Hamdane, F Jühling, E Crouchet, H El Saghire, C Thumann, MA Oudot, ... Gastroenterology 156 (8), 2313-2329. e7, 2019 | 246 | 2019 |
| A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update R Tateishi, K Uchino, N Fujiwara, T Takehara, T Okanoue, M Seike, ... Journal of gastroenterology 54, 367-376, 2019 | 221 | 2019 |
| CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity N Fujiwara, H Nakagawa, K Enooku, Y Kudo, Y Hayata, T Nakatsuka, ... Gut 67 (8), 1493-1504, 2018 | 189 | 2018 |
| Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study R Tateishi, T Okanoue, N Fujiwara, K Okita, K Kiyosawa, M Omata, ... Journal of gastroenterology 50, 350-360, 2015 | 187 | 2015 |
| Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis A Filliol, Y Saito, A Nair, DH Dapito, LX Yu, A Ravichandra, ... Nature 610 (7931), 356-365, 2022 | 183 | 2022 |
| Lipid metabolic reprogramming in hepatocellular carcinoma H Nakagawa, Y Hayata, S Kawamura, T Yamada, N Fujiwara, K Koike Cancers 10 (11), 447, 2018 | 159 | 2018 |
| Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap YA Lee, LA Noon, KM Akat, MD Ybanez, TF Lee, ML Berres, N Fujiwara, ... Nature communications 9 (1), 4962, 2018 | 148 | 2018 |
| Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import V Rodriguez-Bravo, R Pippa, WM Song, M Carceles-Cordon, ... Cell 174 (5), 1200-1215. e20, 2018 | 125 | 2018 |
| Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development X Wang, Q He, C Zhou, Y Xu, D Liu, N Fujiwara, N Kubota, A Click, ... Immunity 56 (1), 58-77. e11, 2023 | 114 | 2023 |
| Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus–infected cells and liver to identify pathways associated with disease development J Lupberger, T Croonenborghs, AAR Suarez, N Van Renne, F Jühling, ... Gastroenterology 157 (2), 537-551. e9, 2019 | 103 | 2019 |
| The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma T Minami, R Tateishi, R Nakagomi, N Fujiwara, M Sato, K Enooku, ... Journal of hepatology 65 (6), 1272-1273, 2016 | 99 | 2016 |
| Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy MN Kinoshita, T Minami, R Tateishi, T Wake, R Nakagomi, N Fujiwara, ... Journal of hepatology 70 (1), 78-86, 2019 | 88 | 2019 |
| Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma K Enooku, H Nakagawa, N Fujiwara, M Kondo, T Minami, Y Hoshida, ... Scientific reports 9 (1), 10663, 2019 | 82 | 2019 |
| Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma F Jühling, N Hamdane, E Crouchet, S Li, H El Saghire, A Mukherji, ... Gut 70 (1), 157-169, 2021 | 74 | 2021 |
| Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease N Fujiwara, N Kubota, E Crouchet, B Koneru, CA Marquez, AK Jajoriya, ... Science translational medicine 14 (650), eabo4474, 2022 | 70 | 2022 |
| Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis S Kawamura, Y Matsushita, S Kurosaki, M Tange, N Fujiwara, Y Hayata, ... The Journal of clinical investigation 132 (11), 2022 | 67 | 2022 |
Yujin HoshidaUniversity of Texas Southwestern Medical CenterCorreu electrònic verificat a utsouthwestern.edu
